Every 8-K that Conexeu Sciences Inc. (CNXU) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow CNXU and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CNXU filings page.
Conexeu Sciences Inc. approved a warrant exercise inducement program offering holders of Existing Warrants—outstanding to purchase up to 4,762,780 shares as of October 21, 2026—one new warrant for each Existing Warrant exercised before 4:00 p.m. Reno time on April 30, 2027. The Existing Warrants have a $2.30 per-share exercise price. Each Inducement Warrant costs $0.001 and can be exercised to purchase one share at $3.00 for 24 months from its issuance.
Inducement Warrant shares are subject to a 2,563,389-share cap until stockholder approval, allocated first to exercise. The board also agreed to register for resale on Form S-1 shares certain holders have received or receive upon exercise, excluding shares held or deemed beneficially owned by company affiliates. For certain holders subject to voluntary pooling agreements, covered securities are released on May 21, 2027.
Conexeu Sciences Inc. issued 1,333,333 Units on October 15, 2026, at $3.00 each for gross proceeds of $3,999,999. Each Unit contains one common share and one warrant to buy one share at $3.00, exercisable for 24 months from issuance. The company also issued 250,000 Special Warrants at $3.00 each for gross proceeds of $750,000; each automatically converts into one share and one warrant upon the earlier of receipt by the British Columbia Securities Commission of the final Canadian prospectus qualifying their distribution in British Columbia or February 16, 2027. The company intends to use the proceeds for working capital and general corporate purposes.
Subscriptions by management and directors for 83,334 Units remain in escrow pending stockholder approval; if approved, $250,002 will be released to the company, and otherwise the funds will be returned. From September 14 through October 15, 2026, Conexeu reported issuing 1,290,000 shares, 1,333,333 Units and 250,000 Special Warrants, which it said collectively exceeded 5% of its issued and outstanding common shares since its last periodic report. Conexeu agreed to file a continuous resale Form S-1 for the shares and Warrant Shares by the 35th calendar day following October 15, 2026, excluding affiliate-held shares.
Conexeu Sciences Inc. (CNXU) reported a series of unregistered equity issuances from June 18, 2026 through September 4, 2026 that in aggregate exceeded 5% of its outstanding common stock, triggering disclosure under Item 3.02. Over this period, the company issued 1,448,368 unregistered shares of common stock and 202,500 unregistered common stock purchase warrants under various consulting, marketing, director, and warrant exercise arrangements.
The largest single transaction occurred on September 4, 2026, when Conexeu issued 762,608 shares upon warrant exercises at $2.30 per share for $1,753,998.40 in gross proceeds, which it intends to use for working capital and general corporate purposes. Additional issuances included cashless and low‑priced warrant exercises and share grants to consultants and directors at deemed prices between $0.001 and $13.96 per share. All securities were issued as "restricted securities" in reliance on private offering exemptions, primarily Rule 506(b) of Regulation D, Section 4(a)(2), and Rule 903(b) of Regulation S.
Conexeu Sciences has completed its 12‑month preclinical P.R.O.O.F (Performance and Regeneration Outcomes of Flowable Collagen) study for the CXU™ tissue‑restoration platform. In animal models, the study met objectives for facial cheek tissue restoration, a large‑volume 200cc‑equivalent model, and injectable performance benchmarks such as injectability and volumizing behavior.
The company emphasizes that CXU™ and Ten‑Minute Tissue™ remain investigational, with no regulatory clearance or commercial launch. Conexeu plans a predicate‑based 510(k) submission for a lead wound‑care device in Q1 2027, targeting a 90‑day FDA review as a first step before pursuing medical aesthetics and other soft‑tissue indications.
Conexeu Sciences Inc. reported the cash exercise of common stock purchase warrants and related share issuances. On June 4, 2026, the company issued 416,667 common shares for gross proceeds of about $166,667 under a warrant exercise incentive program and granted 416,667 new Incentive Warrants.
The Incentive Warrants allow holders to buy one additional share each at $2.30 for 36 months. After this exercise, 410,338 Program Warrants remained outstanding and common shares outstanding were 26,658,330. On June 8, 2026, Conexeu issued 100,000 Performance Warrant Shares at $0.001 per share, raising $100 and bringing total common shares outstanding to 26,758,330.